Table 2.

Echo, ECG, and Functional Outcome Changes on Probenecid and Placebo

	Probenecid			Placebo			P Value
	Group Mean Before	Group Mean After	Within‐Person Change	Group Mean Before	Group Mean After	Within‐Person Change
LV systolic function and chamber size
FS, %	12.7±4.2	14.8±3.8	2.1±1.0	14.7±4.0	13.1±4.3	−1.7±1.0	0.007
Among FS ≤10%	8.5±1.8	13.8±3.7	5.3±1.3	13.5±5.8	10.5±3.4	−3.0±1.3	0.0001
Among FS >10%	15.4±2.5	15.4±3.9	0±1.1	15.6±2.5	14.8±4.0	−0.8±1.1	0.41
EDV, mL	197.9±57.0	183.5±52.2	−14.4±11.8	169.1±40.8	197.4±60.3	28.3±11.8	0.02
ESV, mL	138.1±57.8	128.5±39.0	−9.6±14.3	125.3±35.1	146.2±56.7	20.9±14.3	0.15
Stroke volume, mL	51.3±18.7	56.3±20.8	5.00±4.24	53.4±18.1	50.9±13.0	−2.47±4.24	0.17
LV diastolic function
E/E′ ratio	16.6±14.9	13.6±11.6	−2.95±1.21	14.8±14.6	16.2±17.4	1.32±1.21	0.03
E′ lateral, m/s	0.06±0.04	0.07±0.04	0.009±0.005	0.07±0.04	0.07±0.03	−0.009±0.005	0.009
E′ septal, m/s	0.05±0.02	0.06±0.03	0.005±0.003	0.06±0.02	0.05±0.02	−0.004±0.003	0.07
E wave, m/s	0.74±0.28	0.66±0.32	−0.03±0.03	0.76±0.29	0.67±0.34	−0.05±0.03	0.71
ECG assessments
QT interval, ms	416±34	425±46	9.3±13.3	421±34	429±22	8.4±6.8	0.95
QTc, ms	443±42	464±73	21.0±13.2	448±49	463±57	17.5±18.2	0.86
QRS width, ms	112±13	120±28	8.0±9.3	109±15	106±20	−4.6±5.1	0.12
PR interval, ms	201±42	195±46	−6.0±10.1	192±35	188±23	−6.5±9.6	0.96
Functional assessment
6MWT (feet)	1113±353	1134±356	21.1±24.9	1098±341	1075±384	−22.7±24.9	0.23

Mean within‐person change±SE presented for each treatment arm, from mixed‐effect models including treatment order and treatment order×treatment arm terms, if significant, and random effect of patient included to account for correlated outcomes within patients. P values are presented from these models for treatment arm differences. EDV indicates end diastolic volume; ESV, end systolic volume; FS, fractional shortening; LV, left ventricular; 6MWT, 6‐minute walk test.